The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at a concentration of 2-5 µg/mg lysate.
WB: 1/2000 - 1/10000. Predicted molecular weight: 62 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Transcription factor that specifically recognizes and binds E-box sequences (3'-CANNTG-5'). Efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF. In association with TFEB, activates the expression of CD40L in T-cells, thereby playing a role in T-cell-dependent antibody responses in activated CD4(+) T-cells and thymus-dependent humoral immunity. Specifically recognizes the MUE3 box, a subset of E-boxes, present in the immunoglobulin enhancer. It also binds very well to a USF/MLTF site.
Ubiquitous in fetal and adult tissues.
Involvement in disease
Note=A chromosomal aberration involving TFE3 is found in patients with alveolar soft part sarcoma. Translocation t(X;17)(p11;q25) with ASPSCR1 forms a ASPSCR1-TFE3 fusion protein. Note=Chromosomal aberrations involving TFE3 are found in patients with papillary renal cell carcinoma. Translocation t(X;1)(p11.2;q21.2) with PRCC; translocation t(X;1)(p11.2;p34) with PSF; inversion inv(X)(p11.2;q12) that fuses NONO to TFE3.
Belongs to the MiT/TFE family. Contains 1 basic helix-loop-helix (bHLH) domain.
Sumoylated; does not affect dimerization with MITF.
1 mg HeLa cell lysate was immunoprecipitated with 3µg/mg ab93808 (lane 1) or control IgG (lane 2). 20% of the immunoprecipitates were analysed by Western blot. Bands were analysed using ab93808 at 0.4µg/ml and developed using cheiluminescence.